eMedicine Specialties > Neurology > Neuromuscular Diseases
Periodic Paralyses: Differential Diagnoses & Workup
Updated: Aug 26, 2009
- Overview
- Differential Diagnoses & Workup
- Treatment & Medication
- Follow-up
Differential Diagnoses
Other Problems to Be Considered
Table 3. Differential Diagnosis of Secondary Periodic ParalysesOpen table in new window
Table
| Hypokalemic | Hyperkalemic |
Urinary potassium-wasting syndromes
| |
| Alcohol | Addison disease Chronic renal failure Hyporeninemic Hypoaldosteronism |
| Drugs - Amphotericin B, barium | Ileostomy with tight stoma |
| Renal tubular acidosis | Potassium load |
GI potassium-wasting syndromes
| Potassium-sparing diuretics |
| Hypokalemic | Hyperkalemic |
Urinary potassium-wasting syndromes
| |
| Alcohol | Addison disease Chronic renal failure Hyporeninemic Hypoaldosteronism |
| Drugs - Amphotericin B, barium | Ileostomy with tight stoma |
| Renal tubular acidosis | Potassium load |
GI potassium-wasting syndromes
| Potassium-sparing diuretics |
Table 4. Differential Diagnosis of Other Entities Causing Acute Generalized Weakness
Open table in new window
Table
| Disorder | Pattern and Distribution of Weakness |
| Transient ischemic attacks | Follow CNS distribution (ie, hemiparetic) May have sensory symptoms and signs |
| Sleep attacks | Occur at onset or termination of sleep Last only minutes |
Myelopathy
| Sensory symptoms Presence of a sensory level Sphincter involvement |
| Myasthenia gravis Lambert-Eaton myasthenic syndrome | Subacute in onset Associated autonomic symptoms in LEMS Hyporeflexia in LEMS Abnormal repetitive nerve stimulation Presence of distinct antibodies |
Peripheral neuropathy of acute onset
| Pattern of weakness Absent stretch reflexes |
Toxins
| Clinical presentation |
| Disorder | Pattern and Distribution of Weakness |
| Transient ischemic attacks | Follow CNS distribution (ie, hemiparetic) May have sensory symptoms and signs |
| Sleep attacks | Occur at onset or termination of sleep Last only minutes |
Myelopathy
| Sensory symptoms Presence of a sensory level Sphincter involvement |
| Myasthenia gravis Lambert-Eaton myasthenic syndrome | Subacute in onset Associated autonomic symptoms in LEMS Hyporeflexia in LEMS Abnormal repetitive nerve stimulation Presence of distinct antibodies |
Peripheral neuropathy of acute onset
| Pattern of weakness Absent stretch reflexes |
Toxins
| Clinical presentation |
Workup
Laboratory Studies
Hypokalemic periodic paralyses
Serum potassium level decreases during attacks but not necessarily below normal. Creatine phosphokinase (CPK) level rises during attacks. In a recent study, transtubular potassium concentration gradient (TTKG) and potassium-creatinine ratio (K/C) distinguished primary hypokalemic PP from secondary PP resulting from a large deficit of potassium. Values of more than 3.0 mmol/mmol (TTKG) and 2.5 mmol/mmol (PCR) indicated secondary hypokalemic PP.
A random urine potassium-creatinine ratio (K/C) of less than 1.5 is indicative of poor intake, gastrointestinal loss, and potassium shift into the cells. If hypokalemia is associated with paralysis, one should consider hyperthyroidism or familial or sporadic periodic paralysis.
Some of the medical conditions associated with hypokalemia are included in the table below (modified from Assadi 20087 ).
Table 5. Medical Conditions Associated With Hypokalemia
Open table in new window
Table
| Urine K/C Ratio | Acid Base Status | Other Associated Features | Medical Conditions |
| <1.5 | Metabolic acidosis | Lower GI loss – Laxative abuse, diarrhea | |
| <1.5 | Metabolic alkalosis | Normal BP | Surreptitious vomiting |
| >1.5 | Metabolic acidosis | DKA, type 1 or type 2 distal RTA | |
| >1.5 | Metabolic alkalosis | Normal BP | Diuretic use, Bartter syndrome, Gitelman syndrome |
| ≥1.5 | Metabolic alkalosis | Hypertension | Primary aldosteronism, Cushing syndrome, renal artery stenosis, congenital adrenal hyperplasia, apparent mineralocorticoid excess, Liddle syndrome |
| Urine K/C Ratio | Acid Base Status | Other Associated Features | Medical Conditions |
| <1.5 | Metabolic acidosis | Lower GI loss – Laxative abuse, diarrhea | |
| <1.5 | Metabolic alkalosis | Normal BP | Surreptitious vomiting |
| >1.5 | Metabolic acidosis | DKA, type 1 or type 2 distal RTA | |
| >1.5 | Metabolic alkalosis | Normal BP | Diuretic use, Bartter syndrome, Gitelman syndrome |
| ≥1.5 | Metabolic alkalosis | Hypertension | Primary aldosteronism, Cushing syndrome, renal artery stenosis, congenital adrenal hyperplasia, apparent mineralocorticoid excess, Liddle syndrome |
ECG may show sinus bradycardia and evidence of hypokalemia (flattening of T waves, U waves in leads II, V 2 , V 3 , and V 4 , and ST-segment depression).
Hyperkalemic periodic paralyses
Serum potassium level may increase to as high as 5-6 mEq/L. Sometimes, it may be at the upper limit of normal, and it seldom reaches cardiotoxic levels. Serum sodium level may fall as potassium level rises. This results from sodium entry into the muscle. Water also moves in this direction, causing hemoconcentration and further hyperkalemia. Hyperregulation may occur at the end of an attack, causing hypokalemia. Water diuresis, creatinuria, and an increase in CPK level also may occur at the end of an attack.
ECG may show tall T waves.
Table 6. Diagnostic Studies of Hypokalemic and Hyperkalemic Periodic Paralyses
Open table in new window
Table
| Hypokalemic PP | Hyperkalemic PP | |
| Serum potassium | Mildly depressed; may reach 1-5 mEq/L | Increases from baseline but may not increase beyond normal range |
| Serum CPK | Moderately elevated during attacks | Mildly elevated during attacks |
| ECG | Bradycardia Flat T waves, U waves, ST-segment depression | Tall T waves |
| Hypokalemic PP | Hyperkalemic PP | |
| Serum potassium | Mildly depressed; may reach 1-5 mEq/L | Increases from baseline but may not increase beyond normal range |
| Serum CPK | Moderately elevated during attacks | Mildly elevated during attacks |
| ECG | Bradycardia Flat T waves, U waves, ST-segment depression | Tall T waves |
Other Tests
- Electrodiagnosis
- Nerve conduction studies
- The compound muscle action potential (CMAP) amplitude declines during the paralytic attack, more so in hypokalemic periodic paralysis (PP). Sensory nerve conduction study findings are normal in most patients with PP. Nerve conduction findings may be abnormal when the patient has peripheral neuropathy associated with thyrotoxicosis.
- Repetitive nerve stimulation in hyperkalemic periodic paralysis (PP) may show a decrement in CMAP (accentuated by cooling) that is steadily progressive without tendency to recover as in myasthenia gravis. The amount of decrement is variable and increases with increased frequency of stimulation. In some patients, it is seen only with stimulation greater than 25 Hz.8
- Muscle cooling
- Cooling of muscle to 20°C leads to force reduction and prolonged twitch-relaxation in PC and hyperkalemic PP. Muscle paralysis is prolonged and persistent even after rewarming.
- As the muscle depolarizes at different temperatures in different patients, a muscle temperature of 20-25°C is preferable. This is best achieved by immersing the whole arm in ice water. This alone causes weakness in many patients.
- Short periods of exercise (2-3 1-second short exercises) enhance the weakness and result in a very small CMAP.8
- Exercise test in periodic paralyses
- This is one of the most informative diagnostic tests for PP. The test is based on 2 previously described observations: that CMAP amplitude is low in the muscle weakened by PP and the weakness can be induced by exercise. Recording electrodes are placed over the hypothenar muscle and a CMAP is obtained by giving supramaximal stimuli. The stimuli are repeated every 30-60 seconds for a period of 2-3 minutes, until a stable baseline amplitude is obtained. Two kinds of exercise tests can be performed.
- A short exercise test is one in which the muscle is contracted strongly in isometric conditions for 10-12 seconds. CMAPs are obtained 2 seconds immediately after exercise an then every 10 seconds for 50 seconds. In hyperkalemic PP patients carrying T704M mutations, increase in CMAP amplitude (approximately 23%) occurs. In HypoPP1 and HypoPP2 patients, the increase is not significantly different from the control subjects (about 5%).
- In the long exercise test, the muscle is contracted for 5 minutes, with brief (3- to 4-second) rests every 15 seconds to prevent muscle ischemia. The CMAP is recorded every minute during exercise and every 1-2 minutes after exercise for a period of 30 minutes or until no further decrement is observed in the amplitude of CMAP. Percentage of decrement is calculated by subtracting the smallest amplitude after exercise from the greatest amplitude after exercise and dividing it by the greatest amplitude after exercise. After a brief increase in CMAP amplitude, a decrease of more than 40% in the CMAP amplitude after 20 minutes is considered abnormal. An abnormal result is highly suggestive of PP (98% specificity) but does not distinguish between hyperkalemic, hypokalemic, and thyrotoxic PP. Different electrophysiologic patterns are identified in different group of patients with distinct mutations by using both these tests.
- Table 7. Electrophysiological Patterns to Exercise Testing
Open table in new window
[ CLOSE WINDOW ]Table
Paramyotonia
CongenitaHyperkalemic
Periodic ParalysisHypokalemic
Periodic ParalysisElectrophysiological pattern I IV V Channel mutations Sodium T1313M, R1448C Sodium T704M Calcium R528H Short Exercise Test: Post exercise myotonic potentials Yes No No CMAP amplitude change after First trial Increase or decrease Increase No CMAP amplitude change after second and third trial Gradual increase Gradual increase No Long Exercise Test: Immediate change of CMAP amplitude Decrease Increase No Late change of CMAP amplitude Decrease Decrease Decrease Modified from Fournier et al, 2004.9Paramyotonia
CongenitaHyperkalemic
Periodic ParalysisHypokalemic
Periodic ParalysisElectrophysiological pattern I IV V Channel mutations Sodium T1313M, R1448C Sodium T704M Calcium R528H Short Exercise Test: Post exercise myotonic potentials Yes No No CMAP amplitude change after First trial Increase or decrease Increase No CMAP amplitude change after second and third trial Gradual increase Gradual increase No Long Exercise Test: Immediate change of CMAP amplitude Decrease Increase No Late change of CMAP amplitude Decrease Decrease Decrease
- Needle electrode examination
- Insertional activity: The presence of myotonia usually excludes the diagnosis of hypokalemic PP. In hyperkalemic PP, no abnormality is detectable between attacks. In those patients with both clinical and electrical myotonia, mild to moderate spontaneous activity is seen, consisting of fibrillation potentials, positive sharp waves, and myotonic discharges.
- Myotonia: Electrical myotonia consists of repetitive discharges at rates of 20-80 Hz. The shape of the potentials can be either positive sharp waves or small biphasic waves; the former is seen while moving the needle electrode and the latter following muscle contraction. Another criterion distinct for myotonia is waxing and waning of the amplitude and frequency of the discharges (ie, dive-bomber discharges). These discharges should last a minimum of 500 milliseconds. They should be elicited in at least 3 areas outside the endplate region in order to distinguish minimal electromyographic myotonia from insertional activity. Demonstration of myotonia may be facilitated by potassium administration and cold temperature.
- Motor unit action potential (MUAP): During the paralytic attack, recruitment is reduced, with few voluntary MUAPs. The amplitude and duration of MUAPs may be reduced. In patients who develop myopathy, the MUAPs tend to show decreased amplitude, reduced duration, and increased proportion of polyphasic potentials.
- Nerve conduction studies
- Provocative testing: General precautions for such testing include (1) physician presence during testing, (2) performance of testing in an intensive care setting, (3) avoidance of testing patients with serum potassium disturbances, diabetes mellitus, or renal or cardiac dysfunction, (4) close monitoring of ECG, and (5) capability for rapid electrolyte and glucose testing and correction.
- Hypokalemic periodic paralyses: Provocative testing is dangerous and is not the first line of diagnostic testing.
- Oral glucose loading test: Glucose is given orally at a dose of 1.5 g/kg to a maximum of 100 g over a period of 3 minutes with or without 10-20 units of subcutaneous insulin. Muscle strength is tested every 30 minutes. Full electrolyte profile is tested every 30 minutes for 3 hours and hourly for the next 2 hours. Weakness usually is detected within 2-3 hours, and if not patients should be considered for intravenous (IV) glucose challenge.
- Intravenous glucose challenge: Good IV access is essential and availability of more than one IV line is preferred. Glucose is infused IV over a period of 1 hour at a dose of 3 g/kg to a maximum of 200 g (in water at 2 g/5 mL). If no weakness is detectable at 30 minutes, 0.1 U/kg of IV insulin is given. Insulin can be repeated in 60 minutes if weakness is not detected. Strength is evaluated every 15 minutes for 2 hours. Electrolytes, glucose, and carbon dioxide are measured every 30 minutes and once more after the patient becomes weak. ECG is repeated every 30 minutes. The most dangerous period of the testing is between 75-150 minutes when severe hypoglycemia occurs. This should be reversed immediately.
- Intra-arterial epinephrine test: Two mcg/min of epinephrine is infused into the brachial artery for 5 minutes and the amplitude of the CMAP is recorded from a hand muscle. CMAPs are recorded before, during, and 30 minutes after infusion. The result is considered positive if a decrement of more than 30% occurs within 10 minutes of infusion.
- Hyperkalemic PP: Potassium chloride 0.05 g/kg in a sugar-free liquid is given orally over 3 minutes in a fasting state, just after exercise. If no weakness occurs, an additional amount of potassium chloride (0.10-0.15 g/kg) is given. Electrolyte profile, ECG, and strength are tested every 15 minutes for 2 hours and then every 30 minutes for the next 2 hours. Weakness usually is detected between 90-180 minutes after initiation of testing.
- Hypokalemic periodic paralyses: Provocative testing is dangerous and is not the first line of diagnostic testing.
Histologic Findings
Muscle biopsy is abnormal, more typically in patients with hypokalemic periodic paralysis (PP) than in patients with hyperkalemic periodic paralysis (PP). Histologic findings in hypokalemic PP include the following:
- The most characteristic abnormality is the presence of vacuoles in the muscle fibers. Sometimes, they fill the muscle fibers, and in some patients, groups of vacuoles may be noted. These changes are more marked in hypokalemic PP than in hyperkalemic PP. In the latter, the vacuoles are small and peripherally located. Reports of muscle biopsy findings in PC are few and the vacuolar changes are less frequent.
- Signs of myopathy include muscle fiber size variability, split fibers, and internal nuclei. Muscle fiber atrophy may be present in clinically affected muscles.
- Tubular aggregates may be seen in some patients. Tubular aggregates are seen in type II fibers. They are subsarcolemmal in location. This abnormality is seen only in hypokalemic PP.
- Muscle fiber necrosis is rare.
More on Periodic Paralyses |
| Overview: Periodic Paralyses |
 Differential Diagnoses & Workup: Periodic Paralyses |
| Treatment & Medication: Periodic Paralyses |
| Follow-up: Periodic Paralyses |
| References |
| « Previous Page | Next Page » |
References
Miller TM, Dias da Silva MR, Miller HA, et al. Correlating phenotype and genotype in the periodic paralyses. Neurology. Nov 9 2004;63(9):1647-55. [Medline].
Venance SL, Cannon SC, Fialho D, et al. The primary periodic paralyses: diagnosis, pathogenesis and treatment. Brain. Jan 2006;129(Pt 1):8-17. [Medline].
Matthews E, Labrum R, Sweeney MG, Sud R, Haworth A, Chinnery PF, et al. Voltage sensor charge loss accounts for most cases of hypokalemic periodic paralysis. Neurology. May 5 2009;72(18):1544-7. [Medline].
Arzel-Hezode M, McGoey S, Sternberg D, Vicart S, Eymard B, Fontaine B. Glucocorticoids may trigger attacks in several types of periodic paralysis. Neuromuscul Disord. Mar 2009;19(3):217-9. [Medline].
Donaldson MR, Yoon G, Fu YH, Ptacek LJ. Andersen-Tawil syndrome: a model of clinical variability, pleiotropy, and genetic heterogeneity. Ann Med. 2004;36 Suppl 1:92-7. [Medline].
Dias Da Silva MR, Cerutti JM, Arnaldi LA, Maciel RM. A mutation in the KCNE3 potassium channel gene is associated with susceptibility to thyrotoxic hypokalemic periodic paralysis. J Clin Endocrinol Metab. Nov 2002;87(11):4881-4. [Medline].
Assadi F. Diagnosis of hypokalemia: a problem-solving approach to clinical cases. Iran J Kidney Dis. Jul 2008;2(3):115-22. [Medline].
Streib EW. AAEE minimonograph #27: Differential diagnosis of myotonic syndromes. Muscle Nerve. Sep 1987;10(7):603-15. [Medline].
Fournier E, Arzel M, Sternberg D, et al. Electromyography guides toward subgroups of mutations in muscle channelopathies. Ann Neurol. Nov 2004;56(5):650-61. [Medline].
Levitt JO. Practical aspects in the management of hypokalemic periodic paralysis. J Transl Med. Apr 21 2008;6:18. [Medline].
Elbaz A, Vale-Santos J, Jurkat-Rott K. Hypokalemic periodic paralysis and the dihydropyridine receptor (CACNL1A3): genotype/phenotype correlations for two predominant mutations and evidence for the absence of a founder effect in 16 caucasian families. Am J Hum Genet. Feb 1995;56(2):374-80. [Medline].
Engel AG, Lambert EH, Rosevear JW, Tauxe WN. Clinical and electromyographic studies in a patient with primary hypokalemic periodic paralysis. Am J Med. Apr 1965;38:626-40. [Medline].
Griggs RC. Evaluation and Treatment of Myopathies. 1995. Philadelphia: FA Davis; 318-354.
Hoffman EP, Lehmann-Horn F, Rudel R. Overexcited or inactive: ion channels in muscle disease. Cell. Mar 10 1995;80(5):681-6. [Medline].
Junker J, Haverkamp W, Schulze-Bahr E, et al. Amiodarone and acetazolamide for the treatment of genetically confirmed severe Andersen syndrome. Neurology. Aug 13 2002;59(3):466. [Medline].
Koch MC, Steinmeyer K, Lorenz C. The skeletal muscle chloride channel in dominant and recessive human myotonia. Science. Aug 7 1992;257(5071):797-800. [Medline].
Lin SH, Lin YF, Chen DT, et al. Laboratory tests to determine the cause of hypokalemia and paralysis. Arch Intern Med. Jul 26 2004;164(14):1561-6. [Medline].
McManis PG, Lambert EH, Daube JR. The exercise test in periodic paralysis. Muscle Nerve. Oct 1986;9(8):704-10. [Medline].
Meola G, Sansone V. Treatment in myotonia and periodic paralysis. Rev Neurol (Paris). May 2004;160(5 Pt 2):S55-69. [Medline].
Ptacek L. The familial periodic paralyses and nondystrophic myotonias. Am J Med. Jul 1998;105(1):58-70. [Medline].
Ptacek LJ, Johnson KJ, Griggs RC. Genetics and physiology of the myotonic muscle disorders. N Engl J Med. Feb 18 1993;328(7):482-9. [Medline].
Ruff RL. Slow inactivation: slow but not dull. Neurology. Mar 4 2008;70(10):746-7. [Medline].
Tricarico D, Barbieri M, Mele A, et al. Carbonic anhydrase inhibitors are specific openers of skeletal muscle BK channelof K+-deficient rats. FASEB J. Apr 2004;18(6):760-1. [Medline].
Zhang J, George AL, Griggs RC. Mutations in the human skeletal muscle chloride channel gene (CLCN1) associated with dominant and recessive myotonia congenita. Neurology. Oct 1996;47(4):993-8. [Medline].
Further Reading
Keywords
periodic paralysis, hypokalemia, hyperkalemia, myotonia, paramyotonia congenita, potassium-aggravated myotonia, voltage-sensitive ion channels, voltage-gated ion channels, channelopathy, calcium channels, sodium channels, chloride channels, thyrotoxicosis, periodic paralyses, PP
